

PROVISIONAL PROGRAMME

PATH PROGRAMME KICK-OFF

IGTP Advanced Therapies Programme

Connecting basic and clinical research to advanced therapies.

DATE	5 November 2026
VENUE	IGTP (Polivalent Room; morning) and HUGTiP (Assembly Hall; afternoon)

Block I. Getting to Know the PATH Programme

Polivalent Room – IGTP, Mar Building

10:00 – 10:30	Institutional Welcome and Introduction to the PATH Programme Presentation of the programme's strategic objectives, an update on CERTERA, and a brief introduction to the participating groups. Joan Vidal and Carol Gálvez, PATH Directors.
10:30 – 12:00 Moderator: Marcel·la Franquesa	Getting to Know the PATH Programme – Flash Talks Short presentations by PATH groups showcasing their research areas, capabilities, platforms, and opportunities for collaboration.
12:00 – 13:00	<i>Coffee Break</i>
12:30 – 13:30 Moderators: Elisabeth Castellanos and Carol Gálvez	Moderated Discussion and Networking – Connecting PATH Groups An interactive moderated discussion based on questions and reflections arising from the Flash Talks, aimed at identifying shared needs, common challenges, potential solutions, synergies, and opportunities for collaboration.

Block II. From the Laboratory to the Patient

Assembly Hall – HUGTiP

13:30 – 14:00	Transfer to HUGTiP
---------------	--------------------

PROVISIONAL PROGRAMME

13:30 – 14:30	Lunch HUGTIP Assembly Hall.
14:30 – 15:10 Moderator: Santiago Roura	Session I. Advanced Therapy Manufacturing Manufacturing processes, scale-up, quality, and GMP production. <ul style="list-style-type: none"> • <i>“Presentation title to be confirmed”</i> Clara Boces, Chief R&D Integration and GMP Development (Cellab - CDMO) • <i>“Manufacturing Advanced Therapies: Much More Than Following a Protocol”</i> Cristina Prat-Vidal, Technical Director, Advanced Therapy Manufacturer (Banc de Sang i Teixits) • <i>“Accelerating the Development of Cell Therapies. Thermo Fisher Scientific”</i> Lucía Gómez Pardo, Senior Key Account Manager (Life Sciences Solutions, Thermo Fisher Scientific) • <i>“Accelerating the Transition to Advanced Therapies: Key Technologies for Scaling Up to GMP Manufacturing”</i> Genís Espanyol, Product Manager (Aplitech Biolab)
15:10 – 15:50 Moderator: Joan Vidal	Session II. Regulation, Innovation and Technology Transfer Regulatory requirements, clinical development, legal advice, intellectual property, and technology transfer. <ul style="list-style-type: none"> • <i>“From Science to Clinical Development: Advancing Advanced Therapies”</i> Rossana García, Founder & CEO (Advanthera) • <i>“Innovation Unit Services for Advanced Therapy Projects”</i> Josep Maria Torras, Innovation Project Manager (IGTP) • <i>“Advanced Therapies: From Therapeutic Innovation to Pharmaceutical Quality”</i> Marc Jordà, Head of Quality Assurance and Technical Director (Archivel Farma)
15:50 – 16:20	Coffee Break

PROVISIONAL PROGRAMME

16:20 – 17:00

Moderator: Iñigo Pérez

Session III. Clinical Translation – Experiences and Success Stories

Experiences and opportunities for bringing advanced therapies from the laboratory to patients.

- *“Periscope: The Challenge of Turning a Preclinical Prototype into an Advanced Therapy Medicinal Product for Human Use”*. **Paloma Gastelurrutia**, ASAC Coordinator (Clinical Trials Support Area, Heart Institute, HUGTiP); Senior Clinical Research Manager, ASIC (Clinical Research Support Area, IGTP)
- *“Mesenchymal Stem Cells for Traumatic Spinal Cord Injury and Their Clinical Translation”* **Joan Vidal**, Director of Education (Guttmann Institute)
- *“From the Laboratory to the Patient: The BST Manufacturing Platform”* **Núria Gavalà**, Director of the Advanced Therapies Platform (Banc de Sang i Teixits)
- *“Inducing Immune Tolerance in Autoimmunity Using Tolerogenic Dendritic Cells”* **Eva Martínez-Cáceres**, Head of Immunology, Northern Metropolitan Clinical Laboratory (HUGTiP)

17:00

Closing Remarks

PATH Leadership and IGTP Scientific Directorate

Summary of the day and presentation of the PATH Programme’s upcoming initiatives.